Samsung Biologics readies mRNA vaccine drug substance production

By The Science Advisory Board staff writers

June 1, 2021 -- Samsung Biologics said that it plans to add messenger RNA (mRNA) vaccine drug substance production to its suite of manufacturing capabilities.

The company's current facility in Songdo, South Korea, is expected to be capable of current good manufacturing practice (cGMP) operations for mRNA vaccine drug substance production by the first half of 2022. As a result, Samsung Biologics will be able to provide end-to-end mRNA vaccine manufacturing services, ranging from bulk substances to aseptic fill/finish including labeling and packaging, as well as cold chain storage, according to the vendor.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.